Menu Search
Equities

Coherus BioSciences Inc

8C5:BRN

Coherus BioSciences Inc

Actions
  • Price (CHF)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Coherus BioSciences Inc grew revenues 21.89% from 211.04m to 257.24m while net income improved from a loss of 291.75m to a smaller loss of 237.89m.
Gross margin44.71%
Net profit margin-0.15%
Operating margin8.44%
Return on assets-0.08%
Return on equity--
Return on investment-0.16%
More ▼

Cash flow in USDView more

In 2023, Coherus BioSciences Inc increased its cash reserves by 61.51%, or 39.36m. Cash Flow from Investing totalled 144.64m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 174.88m for operations while cash generated from financing totalled 69.60m.
Cash flow per share0.0416
Price/Cash flow per share26.10
Book value per share-0.7636
Tangible book value per share-1.23
More ▼

Balance sheet in USDView more

Coherus BioSciences Inc has a Debt to Total Capital ratio of 149.83%.
Current ratio1.25
Quick ratio1.09
Total debt/total equity--
Total debt/total capital1.50
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		96.58
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.